NKF K/DOQI GUIDELINES Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis | Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | Bone Metabolism | Hypertension and Antihypertensive Agents | History of K/DOQI

Tables - Tip
Figures - Tip
Acronyms and Abbreviations
Work Group Membership and Evidence Review Team
K/DOQI Advisory Board Members
Foreword
Executive Summary
Background

Clinical Practice Guidelines

• Guideline 1.    Goals of Antihypertensive Therapy in CKD
• Guideline 2.    Evaluation of Patients With CKD or Hypertension
• Guideline 3.    Measurement of Blood Pressure in Adults
• Guideline 4.    Evaluation for Renal Artery Disease
• Guideline 5.    Education on Self-Management Behavior
• Guideline 6.    Dietary and Other Therapeutic Lifestyle Changes in Adults
• Guideline 7.    Pharmacological Therapy: Use of Antihypertensive Agents in CKD
• Guideline 8.    Pharmacological Therapy: Diabetic Kidney Disease
• Guideline 9.   Pharmacological Therapy: Nondiabetic Kidney Disease
• Guideline 10.  Pharmacological Therapy: Kidney Disease in the Kidney Transplant Recipient
• Guideline 11.   Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in CKD
• Guideline 12.   Use of Diuretics in CKD
• Guideline 13.   Special Considerations in Children

Recommendations for Clinical Performance Measures

Appendices

• Appendix 1: Methods Used for Guideline Development
• Appendix 2: MEDLINE Search Strategies
• Appendix 3: Technical Report on Ambulatory Blood Pressure Monitoring in CKD

Work Group Biographies

Acknowledgments

References

K/DOQI Disclaimer